JP5088873B2 - L−アルギニン含有医薬組成物及び飲食品用組成物 - Google Patents
L−アルギニン含有医薬組成物及び飲食品用組成物 Download PDFInfo
- Publication number
- JP5088873B2 JP5088873B2 JP2007524002A JP2007524002A JP5088873B2 JP 5088873 B2 JP5088873 B2 JP 5088873B2 JP 2007524002 A JP2007524002 A JP 2007524002A JP 2007524002 A JP2007524002 A JP 2007524002A JP 5088873 B2 JP5088873 B2 JP 5088873B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- derivative
- arginine
- component
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 title claims description 38
- 229930064664 L-arginine Natural products 0.000 title claims description 38
- 235000014852 L-arginine Nutrition 0.000 title claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- 235000013305 food Nutrition 0.000 title description 22
- 239000000203 mixture Substances 0.000 title description 17
- 235000013361 beverage Nutrition 0.000 title description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 64
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 56
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 33
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 32
- 229960000304 folic acid Drugs 0.000 claims description 32
- 235000019152 folic acid Nutrition 0.000 claims description 32
- 239000011724 folic acid Substances 0.000 claims description 32
- 229930003427 Vitamin E Natural products 0.000 claims description 28
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 28
- 235000019165 vitamin E Nutrition 0.000 claims description 28
- 239000011709 vitamin E Substances 0.000 claims description 28
- 229940046009 vitamin E Drugs 0.000 claims description 28
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 19
- 229960001948 caffeine Drugs 0.000 claims description 17
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 16
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 16
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 11
- 201000001881 impotence Diseases 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 48
- 230000000694 effects Effects 0.000 description 29
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 22
- 229930003268 Vitamin C Natural products 0.000 description 22
- 235000019154 vitamin C Nutrition 0.000 description 22
- 239000011718 vitamin C Substances 0.000 description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 206010003210 Arteriosclerosis Diseases 0.000 description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000005226 corpus cavernosum Anatomy 0.000 description 4
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 organic acid salts Chemical class 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 201000004193 respiratory failure Diseases 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000008321 arterial blood flow Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Description
LA:L−アルギニン
C :カフェイン
VC:アスコルビン酸
VE:α−トコフェロール
FA:葉酸
本発明に用いるL−アルギニンの塩としては、塩酸塩、硫酸塩、硝酸塩等の鉱酸塩、酢酸塩、クエン酸塩等の有機酸塩を挙げることができる。
本発明に用いるカフェインの塩としては、L−アルギニンと同様の塩を用いることができる。
本発明に用いられるビタミンC又はその誘導体としては、特に限定されないが、例えば、パルミチン酸アスコルビル、燐酸Mg−アスコルビル、酢酸アスコルビルなどを用いることができる。
本発明に用いられるビタミンE又はその誘導体としては、特に限定されないが、例えば、酢酸α−トコフェロールなどを用いることができる。
本発明に用いられる葉酸又はその誘導体としては、特に限定されず、通常用いる葉酸又はその誘導体を用いることができる。
本発明の医薬組成物、及び飲食品用組成物は、その組成物中の、成分(A):L−アルギニン又はその塩、成分(B):カフェイン又はその塩、及び成分(C):ビタミンC又はその誘導体、ビタミンE又はその誘導体、及び葉酸又はその誘導体から選択される1種以上、の配合比(モル比)は、L−アルギニンの効果向上の観点から、成分(A):L−アルギニン又はその塩を100とした時、成分(B):カフェイン又はその塩は0.05以上67以下が好ましく、より好ましくは、0.5以上20以下である。また、成分(C)が、ビタミンC又はその誘導体である場合、0.05以上67以下が好ましく、より好ましくは0.5以上20以下である。ビタミンE又はその誘導体である場合は、0.0005以上67以下が好ましく、より好ましくは0.001以上20以下であり、葉酸又はその誘導体である場合は、0.005以上67以下である。
<剤型>
本発明の薬剤は、医薬用組成物以外に、必要な添加剤を配合して、各種投与形態にすることができる。固形経口製剤を調製する場合、賦形剤、必要に応じて結合剤、崩壊剤、滑沢剤、着色剤、矯味剤、矯臭剤等を加えた後、常法により錠剤、顆粒剤、散剤、カプセル剤等とすることができる。経口用液体製剤を調製する場合、矯味剤、緩衝剤、安定化剤、矯臭剤等を加えて常法により内服液剤、シロップ剤、ジェリー剤、エリキシル剤等とすることができる。注射剤を製造する場合、pH調整剤、緩衝剤、安定化剤、等張化剤、局所麻酔剤等を添加し、常法により皮下、筋肉内、静脈内及び陰茎海綿体内用注射剤等とすることができる。軟膏剤を調製する場合、通常使用される基剤、安定剤、湿潤剤、保存剤等を必要に応じて配合し、常法により混合、製剤化することができる。貼付剤を調製する場合、通常の支持体に前記軟膏、クリーム、ゲル、ペースト等を常法により塗布すればよい。また、本発明の薬剤は、成分(A)と、成分(B)と、成分(C)とを別々に調製し、そのキットの形態とすることもできる。
また、薬剤の有効投与量は、患者の体重、年齢、性別、投与方法、体調、症状、剤型等により異なるが、成人に対する経口の場合、成分(A)、(B)及び(C)の合計で、1日当たり0.2g以上5g以下を1回又は2〜数回に分けて服用することが好ましい。貼付剤の場合、1回当たり0.02g以上1g以下含有するテープなどを用いるのが好ましい。また、塗布剤の場合は、1回当たり0.02g以上1g以下含有する軟膏クリームなどを用いる。
<剤型>
本発明に係る飲食品は、飲食品用組成物以外に、賦形剤、増量剤、結合剤、増粘剤、乳化剤、着色料、香料、食品添加物、調味料などと調合されて飲食品として用いることができる。剤型としては、特に限定されないが、ペースト状、液状の状態、ハードカプセル、ソフトカプセルのようなカプセル剤、錠剤、丸剤として、また、粉末状、顆粒状、飴状などの形状に成形することができる。これらは、一般的な製造方法に準じて製造することができる。
また、飲食品の有効喫食量は、年齢、性別、摂取方法、剤型等により異なるが、成分(A)、(B)及び(C)の合計で、1回当たり0.02g以上10g以下であることが好ましく、更に好ましくは0.2g以上5g以下である。
<実施例1〜3、比較例1>
体重約2.5kgの日本白色在来種雄性ウサギを、ペントバルビタールナトリウム(25mg/kg、静脈内注射)麻酔下に、大腿動脈から放血して致死させた後、速やかに陰茎を摘出した。氷冷下のクレブス液中にて白膜を除去し、陰茎海綿体を切離し、長さ約7mm、直径約2mmの円柱状標本を作製した。標本の一端を固定し、他端を張力測定用トランスデューサー(日本光電工業社製「TB−612T」)に接続した。95%酸素と5%炭酸ガスを飽和し、37℃に加温したクレブス中に標本を保持し、各種薬物添加によって生じる等尺性張力変化をペン描きオシログラフ(理科電気社製「R−64」)上に記録した。
<実施例4〜6>
実施例1〜3におけるビタミンCを、ビタミンEとし、添加濃度を1μM(実施例4)、10μM(実施例5)、100μM(実施例6)とした以外は同様に実施した。
<実施例7〜9>
実施例1〜3におけるビタミンCを、葉酸とし、添加濃度を0.01mM(実施例7)、0.1mM(実施例8)、1mM(実施例9)とした以外は同様に実施した。
<実施例10〜15>
添加するビタミン濃度を、ビタミンC100μM、ビタミンE0.1μM、葉酸1μMとし、表4に示す配合で添加し、実施例10〜15とした。対照として、比較例1との比較を行った。
<実施例16>
ビタミンE(70%)(笠野興産社製)0.004kg、葉酸(DSMニュートリションジャパン)0.011kg、無水カフェイン(静岡カフェイン工業所社製)1.11kg、L−アルギニン(協和発酵社製)33.33kg、結晶セルロース(ビバプアー101;レッテンマイヤー社製)1.039kg、ショ糖脂肪酸エステル(S−307F;三菱化学フーズ社製)0.5kgを、ロッキングミキサー(商裕機械社製)に加え、10分間混合した。混合後、目視により分級、ダマの有無を確認した。得られた混合物をカプセルに360mgずつ充填し、カプセル剤を製造した。
Claims (1)
- 成分(A):L−アルギニン又はその塩
成分(B):カフェイン又はその塩
成分(C):ビタミンE又はその誘導体及び葉酸またはその誘導体を併用
を含有してなる、高血圧もしくは***不全の予防、改善及び/又は治療に用いる医薬組成物であって、
成分(A)の100モルに対し、成分(B)を0.05〜67モル及び成分(C)のうち、葉酸又はその誘導体を0.005〜67モル、ビタミンE又はその誘導体を0.0005〜67モルを含有してなる医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007524002A JP5088873B2 (ja) | 2005-07-04 | 2006-06-29 | L−アルギニン含有医薬組成物及び飲食品用組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005195412 | 2005-07-04 | ||
JP2005195412 | 2005-07-04 | ||
PCT/JP2006/313020 WO2007004523A1 (ja) | 2005-07-04 | 2006-06-29 | L-アルギニン含有医薬組成物及び飲食品用組成物 |
JP2007524002A JP5088873B2 (ja) | 2005-07-04 | 2006-06-29 | L−アルギニン含有医薬組成物及び飲食品用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007004523A1 JPWO2007004523A1 (ja) | 2009-06-25 |
JP5088873B2 true JP5088873B2 (ja) | 2012-12-05 |
Family
ID=37604390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007524002A Expired - Fee Related JP5088873B2 (ja) | 2005-07-04 | 2006-06-29 | L−アルギニン含有医薬組成物及び飲食品用組成物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20090149481A1 (ja) |
EP (1) | EP1902710A4 (ja) |
JP (1) | JP5088873B2 (ja) |
WO (1) | WO2007004523A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA102070C2 (uk) * | 2009-12-16 | 2013-06-10 | Общество С Ограниченной Ответственностью "Фармацевтическая Группа "Здоровье" | Застосування фармацевтичної композиції, що містить (s)-2-аміно-5-гуанідинопентанової кислоти (s)-2-аміноглутарат, для лікування і профілактики патологій вагітності |
JP5666161B2 (ja) * | 2010-04-05 | 2015-02-12 | 森永製菓株式会社 | ヘチマ及び一酸化窒素産生物質を含有する飲食物 |
ITMI20110445A1 (it) * | 2011-03-22 | 2012-09-23 | Lo Li Pharma Srl | Formulazione farmaceutica comprendente inositolo. |
TWI761672B (zh) | 2018-04-23 | 2022-04-21 | 日商阿爾卑斯藥品工業股份有限公司 | O-醣苷基類黃酮之組成物 |
US10918654B1 (en) * | 2019-09-23 | 2021-02-16 | Alps Pharmaceutical Ind. Co., Ltd. | Rutin compositions |
US11110109B2 (en) | 2019-10-22 | 2021-09-07 | Alps Pharmaceutical Ind. Co., Ltd. | Water soluble O-glycosyl flavonoid compositions and methods for preparing same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10158170A (ja) * | 1996-12-02 | 1998-06-16 | Takeda Shokuhin Kogyo Kk | アルコール性脂肪肝抑制組成物 |
JP2001048797A (ja) * | 1999-08-06 | 2001-02-20 | Ito En Ltd | 痴呆症治療経口投与剤 |
WO2001019370A1 (fr) * | 1999-09-09 | 2001-03-22 | Shiratori Pharmaceutical Co., Ltd. | Agents d'amelioration de la dyserection |
JP2001187736A (ja) * | 1999-10-20 | 2001-07-10 | Ito En Ltd | 滋養強壮剤及び滋養強壮飲食物 |
US20020122834A1 (en) * | 2000-12-22 | 2002-09-05 | Trant Aileen Sontag | Method and composition for improving fertility health in female and male animals and humans |
JP2002322063A (ja) * | 2001-04-25 | 2002-11-08 | Ito En Ltd | 精神疲労軽減組成物、集中力維持増強組成物及び精神的活力維持増強組成物 |
JP2004352702A (ja) * | 2003-05-27 | 2004-12-16 | Real:Kk | 脂肪代謝促進剤または脂肪代謝促進食品 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
WO2000000212A1 (en) * | 1998-06-26 | 2000-01-06 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
AT411958B8 (de) * | 1998-11-19 | 2004-09-27 | Jhs Privatstiftung | Erfrischungsgetränk zur steigerung der alkohol-abbau-kapazität |
US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
DE102004057758A1 (de) * | 2003-12-03 | 2005-07-07 | Rubenack, Donald S., Bellingham | Synergistische Arginin-Kombination |
-
2006
- 2006-06-29 JP JP2007524002A patent/JP5088873B2/ja not_active Expired - Fee Related
- 2006-06-29 WO PCT/JP2006/313020 patent/WO2007004523A1/ja active Application Filing
- 2006-06-29 EP EP06767637A patent/EP1902710A4/en not_active Withdrawn
- 2006-06-29 US US11/994,605 patent/US20090149481A1/en not_active Abandoned
-
2010
- 2010-03-01 US US12/714,731 patent/US20100160353A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10158170A (ja) * | 1996-12-02 | 1998-06-16 | Takeda Shokuhin Kogyo Kk | アルコール性脂肪肝抑制組成物 |
JP2001048797A (ja) * | 1999-08-06 | 2001-02-20 | Ito En Ltd | 痴呆症治療経口投与剤 |
WO2001019370A1 (fr) * | 1999-09-09 | 2001-03-22 | Shiratori Pharmaceutical Co., Ltd. | Agents d'amelioration de la dyserection |
JP2001187736A (ja) * | 1999-10-20 | 2001-07-10 | Ito En Ltd | 滋養強壮剤及び滋養強壮飲食物 |
US20020122834A1 (en) * | 2000-12-22 | 2002-09-05 | Trant Aileen Sontag | Method and composition for improving fertility health in female and male animals and humans |
JP2002322063A (ja) * | 2001-04-25 | 2002-11-08 | Ito En Ltd | 精神疲労軽減組成物、集中力維持増強組成物及び精神的活力維持増強組成物 |
JP2004352702A (ja) * | 2003-05-27 | 2004-12-16 | Real:Kk | 脂肪代謝促進剤または脂肪代謝促進食品 |
Also Published As
Publication number | Publication date |
---|---|
EP1902710A1 (en) | 2008-03-26 |
EP1902710A4 (en) | 2009-12-02 |
WO2007004523A1 (ja) | 2007-01-11 |
JPWO2007004523A1 (ja) | 2009-06-25 |
US20090149481A1 (en) | 2009-06-11 |
US20100160353A1 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8158170B2 (en) | Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis | |
JP5088873B2 (ja) | L−アルギニン含有医薬組成物及び飲食品用組成物 | |
WO2018193752A1 (ja) | アルカリ性化剤による血液浄化 | |
JPH03501126A (ja) | アルコールへの病理学的渇望の発達を抑制する組成物 | |
JPWO2007072911A1 (ja) | 塩酸サプロプテリンの生体内吸収性を向上させた製剤 | |
WO2003055481A1 (fr) | Inhibiteurs de fibrose des organes | |
JP2024083632A (ja) | 血管拡張剤 | |
JPWO2014112641A1 (ja) | 一酸化窒素濃度上昇剤 | |
JPWO2020080499A1 (ja) | 新規医薬組成物 | |
KR20200053069A (ko) | 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물 | |
JP2002255801A (ja) | 高血圧予防用組成物 | |
JP2015131849A (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
WO2020222302A1 (ja) | 新規医薬組成物 | |
JP6112767B2 (ja) | 血液中の尿酸値を低下させるための組成物 | |
JP2006213628A (ja) | 抗ストレス剤 | |
JP5783699B2 (ja) | 経口組成物 | |
JPWO2007049628A1 (ja) | 血液流動性改善剤 | |
WO2007119502A1 (ja) | 便通改善剤 | |
KR102685723B1 (ko) | 시트르산의 의약적으로 허용 가능한 염, 혹은 그 수화물 또는 그들의 혼합물을 포함하는 의약 조성물 | |
JP2018188381A (ja) | 糖尿病予防・治療用医薬組成物、血糖値改善用食品組成物、及び、糖尿病の予防・治療方法 | |
JP2007246488A (ja) | 消化性潰瘍改善組成物 | |
EP3868216A1 (en) | Agent for suppressing alcohol sickness or hangover caused by alcoholic beverage intake | |
JP2001278786A (ja) | 高尿酸性疾患予防治療剤 | |
WO2021193856A1 (ja) | 腎機能保護剤 | |
TW202346314A (zh) | 具有抗肥胖與抗糖尿病活性的胜肽、包含其之醫藥組成物及包含其之機能性食品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120814 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120907 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150921 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5088873 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |